Saturday, May 30, 2026

by Ryan Simeone, SEKISUI Diagnostics

An evidence-based, office-friendly approach to clearer first-visit decisions.

Vaginal symptoms are among the most common concerns in ambulatory care, yet they remain a frequent source of diagnostic uncertainty. National guidelines emphasize that history alone is not sufficient to accurately diagnose vaginitis and may lead to inappropriate treatment. Instead, clinicians should incorporate symptom assessment, examination, and laboratory testing to identify the cause.^1,3

This uncertainty is often operational as much as clinical. Access to microscopy, staff training, visit length, and follow-up workflows vary across primary care, urgent care, and OB/GYN settings. In community practice, point-of-care assessments such as vaginal pH, potassium hydroxide (KOH) testing, and wet mount microscopy may be underused, and inappropriate prescribing is common when diagnostic confirmation is not obtained.^1,8

Practical strategies can reduce uncertainty in vaginitis presentations where bacterial vaginosis (BV) and trichomoniasis are key considerations. The goal is not to add complexity, but to introduce a pragmatic approach that uses objective data to improve first-visit decision-making.¹

Why vaginitis is hard to diagnose on symptoms alone

CDC guidance groups the infections most frequently associated with vaginal symptoms as BV, trichomoniasis, and vulvovaginal candidiasis (VVC), noting that cervicitis can also cause abnormal discharge. Because these conditions can share overlapping symptoms, symptom-based differentiation is unreliable and can contribute to empiric treatment patterns.¹

Diagnostic uncertainty is compounded by the fact that many infections are minimally symptomatic or asymptomatic. For trichomoniasis, CDC guidelines indicate that a large proportion of infections present with minimal or no symptoms, and untreated infections may persist for extended periods.³

BV is also frequently asymptomatic. The CDC BV guideline notes that BV is highly prevalent and the most common cause of vaginal discharge worldwide, and that in a nationally representative survey, the majority of women with BV were asymptomatic.²

In other words, the absence of “classic” symptoms does not reliably exclude infection, particularly in busy settings where patients may present early, intermittently, or after self-treatment. CDC acknowledges that symptomatic women often use over-the-counter

products before or in addition to evaluation by a provider, which can further blur the clinical picture.¹

The downstream cost of guessing

When diagnostic confirmation is not obtained, the clinical and operational consequences can extend beyond a single prescription. A community practice study evaluating symptomatic women found that point-of-care testing was rarely performed and that inappropriate prescriptions were common. Importantly, among women without BV, trichomoniasis, or VVC, those who received empiric antibiotics and/or antifungals were more likely to return for recurrent symptoms within 90 days than those not treated empirically.⁸

Classic clinical reviews similarly emphasize that vaginitis is common and associated with substantial discomfort and frequent medical visits, and that accurate diagnosis and appropriate management can be challenging in outpatient care.⁹

From a practice perspective, repeat visits, follow-up calls, and treatment cycling create avoidable workload. From a patient perspective, delayed relief and multiple touchpoints can erode trust, especially when symptoms are distressing or stigmatized. Diagnostic uncertainty is often shaped by the realities of clinical practice, including time, available tools, and workflow constraints.^1,8

A “minimum viable certainty” workflow for the first visit

CDC outlines that, in the clinician’s office, the cause of vaginal symptoms can often be determined by a combination of vaginal pH testing, a KOH test, and microscopic examination of a wet mount of fresh discharge samples. When microscopy is not feasible, the same guidance underscores that multiple diagnostic methods are available and that laboratory testing can identify the vaginitis cause in the majority of women.¹

Step 1: Focus on the history to guide testing

Clinicians should elicit key contextual factors that affect risk and interpretation, including sexual practices, menstrual timing, vaginal hygiene (including douching), and any recent self-treatment.¹

Step 2: Use low-lift objective data (pH + KOH ± microscopy)

According to CDC, an elevated vaginal pH (>4.5) is common with BV or trichomoniasis (although trichomoniasis can also be present with a normal pH). Because pH testing is not highly specific, CDC recommends further evaluation with microscopy and KOH testing, noting that an amine odor after addition of KOH suggests BV or trichomoniasis.¹

• Measure vaginal pH with pH paper to identify whether the environment is consistent with BV/trichomoniasis patterns (recognizing limited specificity).¹
• Perform a KOH “whiff” test; immediate amine odor supports BV or trichomoniasis as considerations.¹
• If microscopy is available, examine saline and KOH wet mounts to look for diagnostic features and to support appropriate treatment selection.^1,2,3

Step 3: Choose the diagnostic method that fits your setting

The most effective diagnostic approach is the one your clinic can execute reliably. Public guidance on provider-performed microscopy emphasizes that microscopy requires training, quality practices, and appropriate oversight, which can affect feasibility and consistency across settings.¹

If microscopy is not feasible or reliable, clinics can consider send-out laboratory testing or validated point-of-care tests to obtain objective results. CDC emphasizes that laboratory testing can identify the cause in the majority of women, and that multiple diagnostic methods are available for identifying etiology.¹

Bacterial vaginosis: reduce uncertainty with structured criteria

BV can be diagnosed using clinical criteria (Amsel’s criteria) or laboratory-based scoring systems such as the Nugent score. It reflects a shift in vaginal microbiota and is associated with several behavioral and clinical risk factors.²

In practice, uncertainty can be reduced by standardizing a diagnostic pathway and training staff to apply it consistently. Available diagnostic methods include structured clinical criteria, microscopy-based approaches, and molecular testing.²

Objective testing reduces reliance on symptom interpretation and supports more confident treatment decisions.^2,8

Trichomoniasis: remember the “silent” presentation

Trichomoniasis is common and treatable yet frequently missed due to its often subtle or absent presentation. CDC guidelines emphasize that many infections are asymptomatic and that untreated infections may persist for extended periods.³

This has practical implications for diagnostic strategy. A mild, intermittent, or nonspecific symptom story should not automatically close off the diagnostic pathway, particularly when risk factors or clinical suspicion are present. CDC guidance recommends laboratory testing to determine etiology rather than relying on history alone, and describes in-office

approaches such as pH, KOH, and microscopy as part of clinician evaluation when feasible.^1,3

Studies demonstrate that different testing methods vary in sensitivity, with more advanced methods detecting a greater proportion of infections than microscopy alone.³

Implementation tips: make the diagnostic plan executable

To reduce diagnostic uncertainty at scale, clinics benefit from standardizing a workflow rather than relying on individual clinician preference. Public guidance supports bringing objective results into the visit when possible because symptom overlap, time constraints, and resource variability can make diagnosis harder in routine care.^1,8

• Create a standard intake checklist that includes menstrual timing, douching, self-treatment, and relevant sexual history elements.¹
• Define a default first-visit testing bundle your clinic can perform consistently (pH + KOH, with microscopy when feasible).¹
• Establish clear criteria for when to use point-of-care versus laboratory testing.¹
• Use patient-facing explanations that symptoms overlap and objective testing helps avoid unnecessary antibiotics/antifungals and repeat visits.^1,8

Patient education is important. Clinical guidance consistently reinforces that evaluation of vaginitis includes examination and laboratory testing as part of standard care.⁶

Conclusion

Vaginitis visits are common, and diagnostic uncertainty is a persistent challenge. However, it can be meaningfully reduced. Clinical guidance consistently emphasizes that history alone is insufficient and that targeted examination and diagnostic testing are necessary.^1–3

By adopting a structured workflow that incorporates focused history, objective testing, and a reliable diagnostic approach aligned with clinical setting capabilities, clinicians can improve diagnostic confidence at the first visit and reduce unnecessary treatment and follow-up burden.^1,5

References

1. Centers for Disease Control and Prevention. Diseases characterized by vulvovaginal itching, burning, irritation, odor, or discharge. Sexually Transmitted Infections Treatment Guidelines, 2021. Accessed May 19, 2026. https://www.cdc.gov/std/treatment-guidelines/vaginal-discharge.htm
2. Centers for Disease Control and Prevention. Bacterial vaginosis. Sexually Transmitted Infections Treatment Guidelines, 2021. Accessed May 19, 2026. https://www.cdc.gov/std/treatment-guidelines/bv.htm
3. Centers for Disease Control and Prevention. Trichomoniasis. Sexually Transmitted Infections Treatment Guidelines, 2021. Accessed May 19, 2026. https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm
4. American College of Obstetricians and Gynecologists. Vaginitis. FAQ028. Last reviewed May 2025. Accessed May 19, 2026. https://www.acog.org/womens-health/faqs/vaginitis
5. Hillier SL, Austin M, Macio I, et al. Diagnosis and treatment of vaginal discharge syndromes in community practice settings. Clin Infect Dis. 2021;72(9):1538-1543. doi:10.1093/cid/ciaa260
6. Carr PL, Felsenstein D, Friedman RH. Evaluation and management of vaginitis. J Gen Intern Med. 1998;13(5):335-346. doi:10.1046/j.1525-1497.1998.00101.x